We are live on ! Find out more
DAWN

Day One Biopharmaceuticals
DAWN

Delisted

DAWN was delisted on the 22nd of April, 2026.

Back to rankings

164 hedge funds and large institutions have $1.19B invested in Day One Biopharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 62 increasing their positions, 39 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 39

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 33

1% less funds holding

Funds holding: 166 → 164 (-2)

7% less capital invested

Capital invested by funds: $1.28B → $1.19B (-$96M)

11.94% less ownership

Funds ownership: 104.89% → 92.95% (-12%)

38% less call options, than puts

Call options by funds: $2.08M | Put options by funds: $3.36M

Holders
164
Holders Change
-2
Holders Change %
-1.2%
% of All Funds
2.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
32
Increased
62
Reduced
39
Closed
33
Calls
$2.08M
Puts
$3.36M
Net Calls
-$1.27M
Net Calls Change
+$713K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$76.2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$35M
3
BlackRock
BlackRock
New York
+$20.1M
4
Marshall Wace
Marshall Wace
United Kingdom
+$15.3M
5
ECM
Estuary Capital Management
Minnesota
+$13.5M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$35.6M
2
MC
Maverick Capital
Texas
-$29.4M
3
RCM
RA Capital Management
Massachusetts
-$29.4M
4
Goldman Sachs
Goldman Sachs
New York
-$18.1M
5
VPC
Vestal Point Capital
New York
-$14.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rafferty Asset Management
51
Rafferty Asset Management
New York
$2.02M +$320K +22,975 +17%
Citigroup
52
Citigroup
New York
$1.98M +$1.51M +108,164 +225%
SB
53
Samsara BioCapital
California
$1.87M – – –
D.E. Shaw & Co
54
D.E. Shaw & Co
New York
$1.85M +$45.2K +3,250 +2%
Barclays
55
Barclays
United Kingdom
$1.79M +$84.6K +6,079 +4%
N
56
Nuveen
North Carolina
$1.79M -$312K -22,400 -14%
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$1.68M +$1.33M +95,625 +261%
HWAM
58
Hennion & Walsh Asset Management
New Jersey
$1.54M +$802K +57,601 +91%
Swiss National Bank
59
Swiss National Bank
Switzerland
$1.49M +$41.7K +3,000 +3%
Macquarie Group
60
Macquarie Group
Australia
$1.39M – – –
Two Sigma Advisers
61
Two Sigma Advisers
New York
$1.35M -$118K -8,500 -7%
JCIA
62
Jackson Creek Investment Advisors
Colorado
$1.31M +$1.44M +103,592 New
CP
63
CenterBook Partners
Connecticut
$1.28M +$1.4M +100,735 New
GCP
64
GSA Capital Partners
United Kingdom
$1.24M +$539K +38,771 +65%
Fisher Asset Management
65
Fisher Asset Management
Washington
$1.13M +$220K +15,831 +22%
AQR Capital Management
66
AQR Capital Management
Connecticut
$1.12M -$586K -42,112 -32%
TI
67
Trexquant Investment
Connecticut
$1.11M +$1.22M +87,972 New
TE
68
Tema ETFs
New York
$1.09M +$1.19M +85,761 New
NIM
69
NEOS Investment Management
Connecticut
$1.09M +$95.7K +6,878 +9%
AA
70
ALPS Advisors
Colorado
$1.03M +$170K +12,240 +18%
UBS AM
71
UBS AM
Illinois
$958K +$145K +10,386 +16%
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
$957K -$24.3K -1,747 -2%
MAM
73
Martingale Asset Management
Massachusetts
$905K +$1.29K +93 +0.1%
SG Americas Securities
74
SG Americas Securities
New York
$866K +$951K +68,374 New
AllianceBernstein
75
AllianceBernstein
Tennessee
$862K – – –
1 2
3
4 5

DAWN Hedge Fund Activity: Q4 2024 in Review

164 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2024, worth a combined $1.19B — down 7.5% from $1.28B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of DAWN and 32 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 62 added.

The largest buyer was Fidelity Investments, adding an estimated $76.2M. The largest seller was Viking Global Investors, exiting entirely with an estimated $35.6M sold.

  • 164 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2024, down from 166 in Q3 2024.
  • Funds reported $1.19B of Day One Biopharmaceuticals stock for Q4 2024, down 7.5% quarter-over-quarter.
  • 32 funds opened new Day One Biopharmaceuticals positions in Q4 2024 and 33 closed out, a net change of -1 holder.
  • The largest Day One Biopharmaceuticals buyer in Q4 2024 was Fidelity Investments, an estimated $76.2M added.
  • The largest Day One Biopharmaceuticals seller in Q4 2024 was Viking Global Investors, an estimated $35.6M sold.

Based on aggregated 13F filings for Q4 2024.